Business
Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results
Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results.
About this update from Cardiff Lexington Corporation
[{"type":"text","content":"\r\n\r\n \r\n \r\n Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results\r\n \r\n \r\n\r\n\r\nCardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results\r\n\r\n\r\n\r\n\r\n\r\n\r\n 39.5% increase in FY25 total revenue to $11.5 million compared to FY 2024\r\n 62.7% increase in FY25 gross profit to $7.2 million compared to FY 2024\r\n $1.1 million in income from continuing operations in FY 2025\r\n Strengthening operational team and capital structure to position Company for next phase of growth\r\n LEXINGTON, KY / ACCESS Newswire / March 16, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced financial results for the fourth quarter and full year ended December 31, 2025.\r\n Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, \"2025 was a year of strong strategic execution as we continued to enhance our Nova Ortho and Spine footprint and offerings while making meaningful progress on our long-term goals. Notably, full year revenue increased 39.5% on a GAAP basis in 2025 compared with 2024, supported by our operations in numerous diverse locations throughout Florida and Georgia where we are seeing strong demand for our services. Operationally, we've shifted our focus to more higher value surgical procedures, and our patient volumes continue to increase, with an average of between 270 and 375 patients treated per month across all our locations.\r\n \"During the fourth quarter, we strengthened the Nova Ortho and Spine team with the addition of leading healthcare talent and entered a strategic partnership with Doctors' Memorial Hospital in Perry, Florida to bring our leading services to patients in this area of the state. Subsequent to the close of the quarter, we improved our capital structure with the execution of a 1-for-3 reverse split as a part of our planned uplisting to a major US stock exchange. We believe this will strengthen our capital markets profile and enhance our visibility, liquidity, and access to capital to support our anticipated growth as we continue to bring our world-class care to an underserved patient population,\" Mr. Cunningham concluded.\r\n Full Year 2025 Financial Highlights\r\n Total revenue increased 39.5% to $11.5 million compared with $8.3 million in full year 2024, primarily related to higher patient volume and a shift t...